Taiwan · Delayed Price · Currency is TWD Taho Pharmaceuticals Company Description
Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan.
The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage.
The company also develops TAH2211 Buprenorphine/Naloxone sublingual film for opioid addiction, which is in phase I; TAH2231 Naloxone Buccal film for opioid overdose, which is in phase I; TAH9922 Atomoxetine oral liquid, which is in phase I; and TAH9901 Methylphenidate patch for ADHD treatment, which is in phase I.
Taho Pharmaceuticals Ltd. was founded in 2010 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2010 |
| Industry | Pharmaceutical Preparations |
| Employees | 35 |
| CEO | Shiren S. Lee |
Contact Details
Address: No.550, Ruiguang Road Taipei, 11492 Taiwan | |
| Phone | 886 2 2659 8515 |
| Website | tahopharma.com |
Stock Details
| Ticker Symbol | 6467 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shiren S. Lee | Chief Executive Officer |
| Yu Zhang | Chief Financial Officer |